Hook / Thesis
CareDx (CDNA) has momentum that looks sustainable: the company reported strong preliminary Q1 2026 trends with revenue up 39% year-over-year (Testing Services +48%, Patient & Digital Solutions +33%) and then sharpened focus on those higher-growth assets by agreeing to sell its Lab Products business for $170 million in cash. Add to that early market interest around the Naveris partnership - which is positioned to accelerate adoption of CareDx's molecular/transplant monitoring testing suite - and I remain bullish.
This is an actionable trade idea: enter long at $39.70, place a stop at $33.00, and run the position toward a primary target of $60.00 over a long-term horizon (180 trading days). I lay out the rationale, the numbers that matter, catalysts, and the risks below.
What CareDx Does and Why the Market Should Care
CareDx operates in transplant diagnostics, with products and services centered on non-invasive molecular monitoring (AlloSure), gene expression testing (AlloMap), and complementary digital/patient solutions. The business mix has been shifting: Testing Services and Patient & Digital Solutions now drive the fastest growth, while legacy lab-product sales were a lower-growth, capital-light distraction. Selling Lab Products for $170 million in cash (announced 04/16/2026) signals a strategic pivot to software and recurring testing revenue, where margins and growth are both higher.
Why this matters to investors: recurring testing revenue scales with transplant volumes, improved patient monitoring protocols, and expanded use cases (e.g., earlier rejection detection). The preliminary Q1 2026 print showing 39% overall revenue growth and a 48% gain in Testing Services is concrete evidence that the secular demand story is playing out.
Key Financial/Valuation Readouts
- Market cap: roughly $2.05 billion.
- Enterprise value: approximately $1.97 billion.
- Price-to-sales: ~4.97x (implies trailing revenue in the low hundreds of millions; the multiple reflects the growth profile).
- Free cash flow: $64.85 million, indicating the business generates meaningful cash even while investing for growth.
- Balance sheet/coverage: current ratio ~3.4x and quick ratio ~3.07x, with no meaningful debt on the books, giving CareDx flexibility to deploy the $170M from the Lab Products sale or pursue tuck-ins.
- Profitability: EPS is negative (-$0.16 reported), and ROA/ROE are negative, indicating continued reinvestment and some near-term margin pressure despite healthy revenue growth.
Put simply: the market is assigning premium revenue multiples for high-growth, recurring diagnostic streams. CareDx is trading at elevated multiples relative to slower peers but it also trades below the valuation implied by a successful transition to dominant transplant-testing market share combined with digital solutions monetization.
Naveris - limited public detail, but an important piece of the bull case
Public details on the Naveris relationship are not extensive, but the linkage is important because Naveris brings capabilities (platform and distribution) that could accelerate adoption of CareDx’s testing services. If Naveris helps open commercial doors, shorten sales cycles, or increase per-patient test frequency, the revenue and margin profile could improve materially. I view Naveris as a potential multiplier - not the sole driver - of the company’s ongoing Testing Services growth.
Valuation framing
Valuation is best read relative to execution. At a market cap near $2.05B and EV/Sales of ~4.78x, the stock is priced for continued solid double-digit revenue growth and steady margin improvement. The business already generates FCF (~$64.8M), which supports reinvestment and optionality. The sale of Lab Products for $170M meaningfully improves liquidity and reduces distraction from lower-growth product sales.
Absolute multiples look full versus mature diagnostics companies, but they are not outlandish for a high-growth testing services company that is consolidating market share and expanding digital offerings. If Testing Services growth sustains near the 40-50% range and margins improve, the $60 target is achievable within the 180 trading-day horizon implied below.
Catalysts
- Continued quarterly execution and revenue prints showing Testing Services growth near or above 30-40% (next release after the Q1 prelim).
- Integration updates or expanded commercial agreements tied to Naveris that accelerate test adoption and distribution.
- Use of proceeds from the $170M Lab Products sale to further bolster commercial expansion, buyback shares, or make complementary acquisitions.
- Improved margin trajectory and clearer path to GAAP profitability as scale benefits Testing Services and Patient & Digital Solutions.
- Short-covering rallies given material short interest (latest settlement shows ~8.3M shares short as of 06/30/2026; days-to-cover ~7.3), which can amplify positive news.
Trade plan
My recommended position sizing is tactical - treat this as a medium-to-large conviction idea but limit position size against headline risk (see below).
- Entry: $39.70 (current levels provide a clean entry coincident with 52-week highs).
- Stop loss: $33.00 (a hard cut if momentum reverses and price breaks below recent support structure; keeps downside limited to ~17%).
- Primary target: $60.00 over a long-term horizon (180 trading days). This target assumes continued Testing Services growth, Naveris-driven adoption, and margin expansion that re-rates the multiple toward peer growth analogs.
- Alternate nearer-term target: $48.00 for mid-term traders (45 trading days) if momentum and quarterly prints show steady progress.
Horizon specifics in plain terms: short term (10 trading days) - watch for consolidation or pullback; mid term (45 trading days) - expect fresh quarterly data and early Naveris commercialization signals to move the stock; long term (180 trading days) - aim to capture sustained re-rating as revenue and margins solidify.
Risks and counterarguments
- Regulatory and LDT risk: The diagnostics space has faced regulatory scrutiny and LDT rule changes in recent years. Any new restriction or requirement could slow adoption or add incremental cost.
- Execution risk on Naveris integration: If Naveris adoption stalls or the partnership fails to scale commercially, the upside projection compresses. Public details are limited and execution matters.
- Legal/shareholder overhang: There are ongoing investigations and shareholder inquiries reported in prior years. These can distract management and lead to litigation costs or reputational harm.
- Valuation and momentum risk: The stock is extended technically (RSI > 80) and short interest is meaningful. That combination can create volatility and steep pullbacks if growth disappoints.
- Insider selling headlines: Past insider sales (executive sales via 10b5-1 in January 2026) can be used by the market as negative headlines even when pre-planned.
Counterargument: If you believe the market will instead prize regulatory certainty and low short-term earnings volatility over high-growth optionality, the stock's current multiple may look too rich. A conservative investor could wait for more quarters of confirmed high-margin Testing Services growth or clearer, measurable Naveris-driven revenue before buying.
Conclusion - What would change my mind?
I am bullish because CareDx is a specialized, cash-generative transplant diagnostics business shifting decisively toward high-growth, recurring Testing Services and digital offerings. The $170M Lab Products sale both simplifies the business and provides optionality for commercialization investments or strategic M&A. If Naveris materially accelerates test distribution, the revenue and margin upside justify the current valuation and a re-rating to my $60 target over 180 trading days.
Conversely, I would change my view if (a) Testing Services growth decelerates significantly from the preliminary +48% run-rate; (b) integration with Naveris fails to show commercial traction after multiple quarters; or (c) new regulatory action meaningfully increases costs or restricts the company's testing model. Any of those outcomes would invalidate the re-rating thesis and warrant defensive trimming or exit.
Bottom line: enter a disciplined long at $39.70, stop at $33.00, and target $60.00 over 180 trading days, with a nearer-term mid-horizon plan to take partial profits near $48 if momentum and results validate the play. Keep position sizing mindful of legal and regulatory overhangs and respect the stop if momentum reverses.